Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
OptiBiotix Health ( (GB:OPTI) ) has shared an update.
OptiBiotix Health has secured four significant orders totalling 24 metric tonnes of its flagship weight management ingredient SlimBiome from Taiwanese distributor Meelung Trading, to be delivered in staged shipments throughout 2026, reflecting rapid sales growth since their agreement in mid-2025. Together with a previously announced low six-figure order from a major weight management company and commitments from two other partners, the group has locked in more than £800,000 of non-cancellable orders early in the year, giving it improved visibility, supply-chain efficiencies and pricing leverage as it targets the rapidly expanding “natural alternative to GLP-1” market, where SlimBiome’s clinical backing and regulatory claims position the company for further growth and a stronger competitive footing going into 2026.
The most recent analyst rating on (GB:OPTI) stock is a Hold with a £6.50 price target. To see the full list of analyst forecasts on OptiBiotix Health stock, see the GB:OPTI Stock Forecast page.
Spark’s Take on GB:OPTI Stock
According to Spark, TipRanks’ AI Analyst, GB:OPTI is a Neutral.
The score is weighed down primarily by persistent losses and cash burn despite strong 2024 revenue growth, and by weak technicals showing a sustained downtrend with negative momentum. A debt-free balance sheet provides some support, but valuation remains difficult to justify with negative earnings and no dividend yield provided.
To see Spark’s full report on GB:OPTI stock, click here.
More about OptiBiotix Health
OptiBiotix Health plc is a UK-listed life sciences company focused on developing microbiome-modulating technologies and products aimed at preventing and managing human disease. Its portfolio includes prebiotic and functional ingredients such as SlimBiome, WellBiome, SweetBiotix and Microbiome Modulators within its core business, alongside skincare interests via SkinBioTherapeutics and probiotics through ProBiotix Health, targeting fast-growing global consumer health and weight management markets.
Average Trading Volume: 321,177
Technical Sentiment Signal: Sell
Current Market Cap: £6.61M
For detailed information about OPTI stock, go to TipRanks’ Stock Analysis page.